Reorganization, mergers and acquisitions (M&As),
consolidation and portfolio changes are being evaluated to maintain growth centers in the face of a myriad of serious challenges. Overall, companies are
looking to align with areas of growth opportunity as well as new business strategy and product development paradigms.
Personalized medicine is intended to add several
layers of information into the treatment decision to make it more likely that a patient will perform as desired during treatment or perhaps more accurately,
that we’ll know how a patient will perform during treatment. But personalized medicine is an incredible uphill battle, as many companies and organizations
have seen over the last decade.
Now that the American people have spoken—with about 120 million votes estimated to have been cast as we went to press with this issue—and reelected President Barack Obama to a second term, many of you may be asking, “How will this affect pharma?”